Lueck Christian J, Danesh-Meyer Helen V, Margrie Faith J, Drews-Botsch Carolyn, Calvetti Olivier, Newman Nancy J, Biousse Valérie
Department of Neurology, The Canberra Hospital, Australian National University Medical School, Woden ACT 2606, Australia.
J Clin Neurosci. 2008 Dec;15(12):1340-5. doi: 10.1016/j.jocn.2008.01.014. Epub 2008 Oct 30.
Recent studies suggest that evidence-based medicine is not well translated into everyday practice. Studies of optic neuritis (ON) have generated clear treatment guidelines. Therefore, a survey was mailed to all Australian and New Zealand neurologists and ophthalmologists to evaluate the impact of recent studies on clinical practice. The response rate was 38.9%. Neurologists were more likely to use high dose corticosteroids and disease modifying agents (DMAs), and were more likely to be aware of relevant literature concerning DMAs. Both groups contained a significant minority of practitioners who would use corticosteroids for reasons not substantiated by available evidence. We conclude that most practitioners manage optic neuritis according to existing evidence and guidelines, but many do not. It is essential to instigate high-quality training programs to keep practitioners up-to-date, thereby optimising patient care and justifying the time and expense of large-scale clinical trials.
近期研究表明,循证医学并未很好地转化为日常实践。对视神经炎(ON)的研究已产生了明确的治疗指南。因此,我们向所有澳大利亚和新西兰的神经科医生和眼科医生邮寄了一份调查问卷,以评估近期研究对临床实践的影响。回复率为38.9%。神经科医生更倾向于使用高剂量皮质类固醇和疾病修正药物(DMAs),并且更有可能了解有关DMAs的相关文献。两组中都有相当一部分从业者会出于现有证据未证实的原因使用皮质类固醇。我们得出结论,大多数从业者根据现有证据和指南来处理视神经炎,但仍有许多人并非如此。开展高质量的培训项目以让从业者跟上最新进展至关重要,从而优化患者护理,并使大规模临床试验的时间和费用具有合理性。